Treatment for Cardiovascular Diseases

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Klinik am See - Ruedersdorf, Rüdersdorf, Germany
Cardiovascular Diseases+2 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD Evaluate the distribution of Lp(a) value in participants with documented history of ASCVD by demographics and regions

Eligible Conditions

  • Cardiovascular Diseases
  • Atherosclerotic Cardiovascular Diseases

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Cardiovascular Diseases

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Up to approximately 2 weeks

Week 2
Lp(a) Levels
Lp(a) Levels stratified by demographics and region
Number of participants with elevated Lp(a) with documented history of ASCVD

Trial Safety

Safety Progress

1 of 3

Other trials for Cardiovascular Diseases

Trial Design

0 Treatment Group

20000 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 2 weeks
Closest Location: UCHealth Memorial Central · Colorado Springs, CO
Photo of colorado 1Photo of colorado 2Photo of colorado 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Cardiovascular Diseases
0 CompletedClinical Trials

Who is running the clinical trial?

AmgenLead Sponsor
1,279 Previous Clinical Trials
1,280,643 Total Patients Enrolled
14 Trials studying Cardiovascular Diseases
35,822 Patients Enrolled for Cardiovascular Diseases
MDStudy DirectorAmgen
824 Previous Clinical Trials
850,225 Total Patients Enrolled
7 Trials studying Cardiovascular Diseases
8,619 Patients Enrolled for Cardiovascular Diseases

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.